

Patent

Attorney

Docket No. GGD-31611-PCT-US

09, 980516
JC10 Rec'd PCT/PTO 0 2 NOV 2001

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.: GGD-31611-PCT-US	Serial No: Unknown
	Applicant: Michel Bergeron, et al.	Group Art Unit: Unknown 1644
	Filing Date: Herewith	

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Date	Patentee	U.S. Class	Sub-Class	Filing Date
PNT	A1	5,013,556	05-07-91	Woodle et al.	424	450	10-20-89
	A2						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial		Document Number	Publication Date	Country	Int'l Class	Sub-Class	Translation (Yes/No)
PNT	B1	0 286 418 A1	12-10-88	EPO	A 61K	9/50	N/A
	B2	96/25147	08-22-96	WO	A61K	9/127	N/A
	B3	96/10399	04-11-96	WO	A61K	31/00	N/A
	B4	96/10585	04-11-96	WO	C07K	17/06	N/A

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
PNT		DESORMEAUX A. ET AL.: "Targeting HIV with liposome encapsulated antivirals" ZBL. BAKT., vol. 282, April 1995 (1995-04), pages 225-231
		PHILLIPS N.C.: "Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status" IMMUNOL., vol. 152, 1994, pages 3168-3174
		DESORMEAUX A. ET AL.: "Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection" DRUG TARGETING, vol. 6, no. 1, 1998, pages 1-15

Examiner	Date Considered 8/9/04
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.: GGD-31611-PCT-US	Serial No: Unknown
	Applicant: Michel Bergeron, et al.	Group Art Unit: Unknown
	Filing Date: Herewith	1644

Examiner Initial		
Pnk		MARUYAMA K. ET AL.: "Possibility of active targeting to tumor tissues with liposomes" ADV DRUG DELIV REVIEWS, vol 40, 10 October 1999 (1999-10-10), pages 89-102
		MENEZES DE D E L ET AL.: "Cellular Trafficking and Cytotoxicity of Anti-CD19-Targeted Liposomal Doxorubicin In B Lymphoma Cells" JOURNAL OF LIPOSOME RESEARCH, US, MARCEL DEKKER, NEW YORK, vol 9, no 2, May 1999 (1999-05), pages 199-228
		LUNDBERG B. B. ET AL.: "Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin" INT J PHARMAC, vol 205, September 2000 (2000-09), pages 101-108
		BESTMAN-SMITH J. ET AL.: "Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1" BIOCHIM BIOPHYS ACTA, vol. 1468, 29 September 2000 (2000-09-29), pages 161-174
		BESTMAN-SMITH J. ET AL.: "Targeting cell-free HIV and virally infected cells with anti HLA-DR immunoliposomes containing amphotericin B" AIDS, vol. 14, 10 October 2000 (2000-10-10), pages 2457-2465
		DUFRENE I. ET AL.: "Targeting lymph nodes with liposomes bearing anti-HLA-DR F2' fragments" BIOCHIM BIOPHYS ACTA, vol. 1421, 15 October 1999 (1999-10-15), pages 284-294
↓		ZELPHATI ET AL.: "Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes" ANTISENSE RESEARCH AND DEVELOPMENT, vol. 3, 1993, pages 323-338

Examiner <i>PLN</i>	Date Considered <i>8/9/01</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

GGD-3161 CT-US

Application Number

09/980,516

Applicant(s)

BERGERON, Michel G. et al.

Filing Date

November 2, 2001

Group Art Unit

1644
To be assigned

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PNH Chun, T.-W. et al. (1998). "Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection". Proc. Natl. Acad. Sci. USA. Vol. 95: 8869-8873.

Cantin, R. et al. (1997). "The Presence of Host-Derived HLA-DR1 on Human Immunodeficiency Virus Type 1 Increases Viral Infectivity". Journal of Virology, Vol. 71(3): 1922-1930

Finzi, D. et al. (1997). "Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy". Science, Vol 278: 1295-1300.

Finzi, D. et al. (1999). "Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy". Nature Medicine, Vol. 5(5):512-517.

Saarloos, M.-N. et al. (1997). "Detection of HLA-DR Associated with Monocytotropic, Primary, and Plasma Isolates of Human Immunodeficiency Virus Type 1". Journal of Virology, Vol. 71(2): 1640-1643.

✓ Tremblay, M. J. et al. (1998). "The acquisition of host-encoded proteins by nascent HIV-1". Immunology Today, Vol. 19(8): 346-351.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.